Company intelligence / Profile preview
G1 Therapeutics, Inc.
Research Triangle Park, North Carolina, United Statesg1therapeutics.com ↗
- Ownership
- Public · GTHX
- Development stage
- Commercial
01
Overview
G1 Therapeutics has a commercial product COSELA (trilaciclib), which is FDA-approved for use in extensive-stage small cell lung cancer. The company has multiple ongoing Phase 2 and Phase 3 clinical trials evaluating trilaciclib in various cancer indications including colorectal, breast, lung, and bladder cancers. Initial results from the pivotal Phase 3 PRESERVE 1 trial in colorectal cancer were expected in February 2023. The company is exploring trilaciclib's potential synergistic effects with chemotherapy, antibody drug conjugates (ADCs), and checkpoint inhibitors.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesCDK4/6 inhibitorsSelective estrogen receptor degraders (SERD)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on G1 Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G1 Therapeutics, Inc..